No need for H(2)-antagonists in premedication regimens for paclitaxel infusions: less is more

The theoretical basis for use of histamine 2 (H(2))-receptor inhibitors to prevent hypersensitivity reactions for paclitaxel infusions is weak. This Editorial discusses a clinical study showing that ranitidine is not indicated any more in this setting and puts this in the context of other valuable e...

Descripción completa

Detalles Bibliográficos
Autores principales: Gelderblom, Hans, Zwaveling, Juliette
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Editorial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7987749/
https://www.ncbi.nlm.nih.gov/pubmed/33762719
http://dx.doi.org/10.1038/s41416-021-01316-x
_version_ 1783668670474485760
author Gelderblom, Hans
Zwaveling, Juliette
author_facet Gelderblom, Hans
Zwaveling, Juliette
author_sort Gelderblom, Hans
collection PubMed
description The theoretical basis for use of histamine 2 (H(2))-receptor inhibitors to prevent hypersensitivity reactions for paclitaxel infusions is weak. This Editorial discusses a clinical study showing that ranitidine is not indicated any more in this setting and puts this in the context of other valuable efforts leaving non-evidence-based interventions behind us.
format Online
Article
Text
id pubmed-7987749
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-79877492021-03-24 No need for H(2)-antagonists in premedication regimens for paclitaxel infusions: less is more Gelderblom, Hans Zwaveling, Juliette Br J Cancer Editorial The theoretical basis for use of histamine 2 (H(2))-receptor inhibitors to prevent hypersensitivity reactions for paclitaxel infusions is weak. This Editorial discusses a clinical study showing that ranitidine is not indicated any more in this setting and puts this in the context of other valuable efforts leaving non-evidence-based interventions behind us. Nature Publishing Group UK 2021-03-24 2021-05-11 /pmc/articles/PMC7987749/ /pubmed/33762719 http://dx.doi.org/10.1038/s41416-021-01316-x Text en © The Author(s), under exclusive licence to Cancer Research UK 2021
spellingShingle Editorial
Gelderblom, Hans
Zwaveling, Juliette
No need for H(2)-antagonists in premedication regimens for paclitaxel infusions: less is more
title No need for H(2)-antagonists in premedication regimens for paclitaxel infusions: less is more
title_full No need for H(2)-antagonists in premedication regimens for paclitaxel infusions: less is more
title_fullStr No need for H(2)-antagonists in premedication regimens for paclitaxel infusions: less is more
title_full_unstemmed No need for H(2)-antagonists in premedication regimens for paclitaxel infusions: less is more
title_short No need for H(2)-antagonists in premedication regimens for paclitaxel infusions: less is more
title_sort no need for h(2)-antagonists in premedication regimens for paclitaxel infusions: less is more
topic Editorial
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7987749/
https://www.ncbi.nlm.nih.gov/pubmed/33762719
http://dx.doi.org/10.1038/s41416-021-01316-x
work_keys_str_mv AT gelderblomhans noneedforh2antagonistsinpremedicationregimensforpaclitaxelinfusionslessismore
AT zwavelingjuliette noneedforh2antagonistsinpremedicationregimensforpaclitaxelinfusionslessismore

Ejemplares similares